Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 11/20 | 0.44 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541595 | 1.00 | ADRB3 (0.44) | ADRB3BACE1ADRB1EP300SLC2A1 | |
| SCHEMBL6541590 | 1.00 | ADRB3 (0.44) | ADRB3BACE1ADRB1EP300SLC2A1 | |
| SCHEMBL4472057 | 0.90 | ADRB3 (0.45) | ADRB3BACE1ADRB1SLC2A1ADRB2 | |
| SCHEMBL4472051 | 0.90 | ADRB3 (0.45) | ADRB3BACE1ADRB1SLC2A1ADRB2 | |
| SCHEMBL6241306 | 0.90 | ADRB3 (0.45) | ADRB3BACE1ADRB1SLC2A1ADRB2 | |
| SCHEMBL6539637 | 0.89 | ADRB3 (0.39) | ADRB3BACE1ADRB1ADRB2 | |
| SCHEMBL6539642 | 0.89 | ADRB3 (0.39) | ADRB3BACE1ADRB1ADRB2 | |
| SCHEMBL6539649 | 0.89 | ADRB3 (0.39) | ADRB3BACE1ADRB1ADRB2 | |
| SCHEMBL6677313 | 0.87 | ADRB3 (0.45) | ADRB3BACE1ADRB1SLC2A1 | |
| SCHEMBL4461459 | 0.87 | ADRB3 (0.61) | ADRB3BACE1ADRB1ADRB2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | ADRB3 58/4885BACE1 3900/4885ADRB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.